Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world poor prognostic impact of del(1p32) in newly diagnosed multiple myeloma among Asian populations

View Full Paper
Ask AI
Bookmark
Share

Authors

WTWenjiao TangLZLi Zhang

Discussion

Loading...

Member takes

Overview

This analysis reveals del(1p32) worsens overall survival and progression-free survival in newly diagnosed multiple myeloma patients, suggesting a need for tailored therapies.

Key Points

  • To evaluate the prevalence and prognostic implications of del(1p32) in newly diagnosed multiple myeloma among Asian populations.
  • Retrospective analysis of 279 NDMM patients with clinical and cytogenetic data
  • Assessment of del(1p32) impact on survival through Kaplan–Meier and Cox regression
  • Consideration of co-occurring high-risk cytogenetic abnormalities and transplant status
  • 5.0% of patients harbored del(1p32) with significantly shorter overall survival
  • Patients with del(1p32) had a median overall survival of 25.0 months compared to 34.0 months without
  • Patients undergoing autologous stem cell transplantation showed a trend toward shorter progression-free survival with del(1p32)

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1d5https://doi.org/10.1182/blood-2025-7514
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone2025 · 3 citations
  2. 2P21 | THE LONG TERM PROGNOSTIC IMPACT OF CHROMOSOME 1 ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS2026
  3. 31p and 1q: Partners in crime in multiple myeloma.2024
  4. 4[The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].2024 · 1 citations
  5. 5Outcomes of de novo del(17p) in multiple myeloma.2026